Page 3 - Jonathane Rosenberg News Today : Breaking News, Live Updates & Top Stories | Vimarsana

email article Adding a targeted agent to chemotherapy failed to improve survival as initial therapy for metastatic urothelial carcinoma, a randomized trial showed. Median overall survival (OS) was about 14 months with cisplatin-containing chemotherapy when paired with either placebo or the angiogenesis inhibitor bevacizumab (Avastin). Progression-free survival (PFS), a secondary endpoint, favored the bevacizumab arm (8.0 vs 6.7 months). Grade ≥3 adverse events (AEs) occurred in a similar proportion of patients in each arm, although bevacizumab-related toxicities occurred more often wi...

 E-Mail A new type of drug that helps target chemotherapy directly to cancer cells has been found to significantly increase survival of patients with the most common form of bladder cancer, according to results from a phase III clinical trial led in the UK by Queen Mary University of London and Barts Health NHS Trust. The results are published in the New England Journal of Medicine and were presented at the 2021 American Society of Clinical Oncology's Genitourinary Cancers Symposium. Urothelial cancer is the most common type of bladder cancer (90 percent of cases) and can also be found in ...